Allergy Choices: The Four Evidence-Based Treatment Options

The four evidence-based treatment categories are: (1) pharmacotherapy — intranasal corticosteroids and second-generation antihistamines, first-line per ARIA for mild disease, suppressive only; (2) subcutaneous immunotherapy (SCIT / allergy shots) — disease-modifying, Cochrane symptom SMD −0.73, 3–5 year course now accessible at home for eligible patients via Curex ($129/month); (3) allergen avoidance — useful as an adjunct but rarely sufficient as monotherapy for aeroallergens; and (4) FDA-approved sublingual tablets for the specific allergens they cover (grass, ragweed, dust mite). The right choice depends on symptom severity, which specific allergen drives symptoms, and whether the patient can sustain a 3–5 year treatment commitment.

Pharmacotherapy — intranasal corticosteroids and second-generation antihistamines — is appropriate first-line treatment for mild and moderate-persistent allergic rhinitis per ARIA guidelines. It provides fast symptom relief: intranasal steroids reduce nasal symptom scores by approximately 31.7% and antihistamines by approximately 12% (Matricardi 2011 indirect comparison). However, pharmacotherapy is suppressive rather than disease-modifying. Symptoms return immediately upon cessation because the underlying IgE sensitization is unchanged. For patients with persistent moderate-to-severe symptoms despite optimized pharmacotherapy, or for patients who prefer to eventually reduce medication dependence, SCIT immunotherapy offers a disease-modification pathway that pharmacotherapy cannot provide.

Avoidance is useful as an adjunct strategy but is rarely sufficient as monotherapy for aeroallergens. Cat allergen Fel d 1 has been detected in 99.9% of US homes, including cat-free homes, according to NHANES data. Dust mite allergen is ubiquitous in bedding, carpets, and upholstery in humid climates. Pollen avoidance is limited by outdoor exposure and air conditioning. Avoidance can reduce but not eliminate meaningful allergen load. When avoidance alone is insufficient and symptoms persist despite pharmacotherapy, immunotherapy represents the next treatment tier per Cox L et al. (JACI 2011;127[1 Suppl]:S1–S55, AAAAI/ACAAI/JCAAI Practice Parameter).

Both clinic-administered and at-home SCIT deliver the same subcutaneous immunotherapy that induces allergen tolerance via IgG4 blocking antibody and T-regulatory cell mechanisms — the gold-standard disease-modifying pathway with Cochrane symptom SMD −0.73 across 51 RCTs. The difference is setting: traditional clinic SCIT requires approximately 39 Year-1 visits with mandatory 30-minute post-injection observation on-site. At-home SCIT with Curex delivers that same serum as weekly self-administered shots — a board-certified allergist confirms candidacy, prescribes the extract, and supervises the first injection and every dose change live over Zoom via telehealth; an epinephrine auto-injector is prescribed and confirmed on hand before the first dose; and patients self-observe after each dose. For eligible maintenance-phase patients, at-home SCIT achieves the same immunologic outcome without the clinic-visit commitment that causes 23.9% of starters to never return.

Immunotherapy is the right choice when: (1) symptoms are persistent and moderate-to-severe despite an adequate trial of pharmacotherapy (intranasal corticosteroid plus second-generation antihistamine per Cox 2011 PP3); (2) IgE sensitization to a specific allergen is confirmed by skin-prick test or serum-specific IgE and matches the patient's symptoms; and (3) the patient prefers disease modification — the ability to eventually reduce or stop medications — over indefinite suppression. Immunotherapy is also strongly indicated for Hymenoptera venom allergy, where the alternative is potentially fatal anaphylaxis, and for pediatric patients with rhinitis where preventing asthma development is a priority (PAT study OR 4.6 at 10 years, Jacobsen 2007). For mild seasonal symptoms well-controlled by OTC antihistamines, pharmacotherapy is a reasonable and cost-effective first choice.

Dropout is the most significant practical factor when choosing SCIT. Tkacz JP et al. (Curr Med Res Opin 2021;37:957–965, MarketScan n=103,207) found that 23.9% of US SCIT starters never returned after their first injection, and only 43.9% reached maintenance. Because SCIT maximum benefit requires completing a 3–5 year course, the investment of 39+ Year-1 clinic visits is largely wasted if the patient drops out before year 2. At-home SCIT through Curex directly addresses this barrier: weekly self-administered shots eliminate commute and waiting-room time, making it far easier to stay on schedule. For patients whose primary obstacle to SCIT completion was the clinic-visit burden — not the shots themselves — at-home SCIT is a structurally more adherence-friendly path to the same disease-modification outcome.